Section edited by: Yong-Xiao Wang
The primary objective of this section is to promote significant enhancements in etiology, mechanistic understanding, prevention, diagnosis, and therapies of cardiovascular diseases. This section covers epidemiological investigations, clinical trials or observational studies, novel technologies or instruments, human biology, cell or animal models, mechanism investigations, genomics, biomarkers, bioengineering, bioinformatics, drug discovery and development, gene therapies, drug and gene deliveries, biomaterial utilization, and healthcare regulation or policy of all cardiovascular diseases, including but not limited to, heart attack, cardiac arrhythmias, heart failure, heart valve disease, congenital heart disease, heart muscle disease (cardiomyopathy), stroke, hypertension, coronary artery disease, atherosclerosis, pulmonary hypertension, and aneurysm.